ADC Control Human IgG1-vcMMAE (DAR4, solution)
Based on 1 publication(s) in Google Scholar
ADC Control Human IgG1-vcMMAE (DAR4, solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575).
For research use only. We do not sell to patients.
- Purity : 98.08%
- Molecular Weight:147946 (average)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99001
Human IgG1 kappa, Isotype Control -
HY-15162
Monomethyl auristatin E -
HY-164152A
ADC Control Human IgG1-Deruxtecan (DAR 8) -
HY-P99107A
Brentuximab vedotin (solution) -
HY-P99151
Brentuximab -
HY-164668
ADC Control Human IgG1-SN-38 -
HY-138298
Trastuzumab deruxtecan (solution) -
HY-P99045
Sacituzumab -
HY-141601
Telisotuzumab vedotin -
HY-141598
Datopotamab deruxtecan (solution) -
HY-P99016B
Enfortumab vedotin-ejfv (solution) -
HY-P9907
Trastuzumab
Publications Citing Use of MedChemExpress (MCE) ADC Control Human IgG1-vcMMAE (DAR4, solution)
More
Biological Activity
Description
In Vitro
Antibody-drug conjugates (ADCs) covalently link a highly efficient small molecule toxin to an antibody through a suitable linker. For therapeutic antibody-drug conjugates (ADCs) in cancer treatment, the antibody targets a specific antigen on the surface of tumor cells with high binding affinity, and then the intact ADC is internalized by the tumor cells along with the antigen and digested in lysosomes to release the antitumor toxin [1].
VcMMAE (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[2].
MMAE sensitizes colorectal and pancreatic cancer cells to IR in a time- and dose-dependent manner associated with mitotic arrest. Radiosensitization is manifested as decreased clonogenic survival and increased DNA double-strand breaks in irradiated cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 147946 (average)
-
Color Colorless to light yellow
-
SMILES
[ADC Control Human IgG1-vcMMAE (DAR4, solution)]
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tushar D Nichakawade, et al. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. Nature. 2024 Apr;628(8007):416-423. [Content Brief]
[2]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. [Content Brief]
[3]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ADC Control Human IgG1-vcMMAE (DAR4, solution) Related Classifications
HY-164153 Related Classifications
Powered by Bioz